메뉴 건너뛰기




Volumn 20, Issue 5, 2008, Pages 509-516

PET scanning and prognosis in Hodgkin's lymphoma

Author keywords

Hodgkin's lymphoma; Positron emission tomography; Prognosis

Indexed keywords

3' FLUOROTHYMIDINE F 18; BLEOMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; PREDNISONE; PROCARBAZINE; VINCRISTINE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

EID: 59649119213     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32830b88d3     Document Type: Review
Times cited : (9)

References (19)
  • 1
    • 0037567428 scopus 로고    scopus 로고
    • Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease
    • Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348:2386-2395.
    • (2003) N Engl J Med , vol.348 , pp. 2386-2395
    • Diehl, V.1    Franklin, J.2    Pfreundschuh, M.3
  • 2
    • 23044452477 scopus 로고    scopus 로고
    • Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group
    • Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23:4634-4642.
    • (2005) J Clin Oncol , vol.23 , pp. 4634-4642
    • Meyer, R.M.1    Gospodarowicz, M.K.2    Connors, J.M.3
  • 3
    • 0032548107 scopus 로고    scopus 로고
    • A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease
    • Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506-1514.
    • (1998) N Engl J Med , vol.339 , pp. 1506-1514
    • Hasenclever, D.1    Diehl, V.2
  • 4
    • 0035871347 scopus 로고    scopus 로고
    • Comparison of prognostic models in patients with advanced Hodgkin's disease
    • Gobbi PG, Zinzani PL, Broglia C, et al. Comparison of prognostic models in patients with advanced Hodgkin's disease. Cancer 2001; 91:1467-1478.
    • (2001) Cancer , vol.91 , pp. 1467-1478
    • Gobbi, P.G.1    Zinzani, P.L.2    Broglia, C.3
  • 5
    • 34748836474 scopus 로고    scopus 로고
    • Is [(18)F]fluorodeoxyglucose positron emission tomography the ultimate tool for response and prognosis assessment?
    • Brepoels L, Stroobants S. Is [(18)F]fluorodeoxyglucose positron emission tomography the ultimate tool for response and prognosis assessment? Hematol Oncol Clin North Am 2007; 21:855-869.
    • (2007) Hematol Oncol Clin North Am , vol.21 , pp. 855-869
    • Brepoels, L.1    Stroobants, S.2
  • 6
    • 2642613656 scopus 로고    scopus 로고
    • Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglu-cose
    • Römer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglu-cose. Blood 1998; 91:4464-4471.
    • (1998) Blood , vol.91 , pp. 4464-4471
    • Römer, W.1    Hanauske, A.R.2    Ziegler, S.3
  • 7
    • 34247855900 scopus 로고    scopus 로고
    • PET and PET/CT for response evaluation in lymphoma: Current practice and developments
    • Brepoels L, Stroobants S, Verhoef G. PET and PET/CT for response evaluation in lymphoma: current practice and developments. Leuk Lymphoma 2007; 48:270-282.
    • (2007) Leuk Lymphoma , vol.48 , pp. 270-282
    • Brepoels, L.1    Stroobants, S.2    Verhoef, G.3
  • 8
    • 34548486030 scopus 로고    scopus 로고
    • Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25:3746-3752. This is the first clinical trial to demonstrate that FDG-PET after 2×ABVD is the only independent factor for the prediction of relapse in Hodgkin's lymphoma. This has important consequences toward the further therapeutic management in patients with Hodgkin's lymphoma, independent on the IPS.
    • Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25:3746-3752. This is the first clinical trial to demonstrate that FDG-PET after 2×ABVD is the only independent factor for the prediction of relapse in Hodgkin's lymphoma. This has important consequences toward the further therapeutic management in patients with Hodgkin's lymphoma, independent on the IPS.
  • 9
    • 33751576028 scopus 로고    scopus 로고
    • FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease
    • Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006; 107:2678-2687.
    • (2006) Cancer , vol.107 , pp. 2678-2687
    • Kostakoglu, L.1    Goldsmith, S.J.2    Leonard, J.P.3
  • 10
    • 66249138001 scopus 로고    scopus 로고
    • Prospective evaluation on the value of FDG-PET/CT for response assessment in DLBCL after 1 week of R-CHOP (abstract 204). 10th International conference on malignant lymphoma ICML Lugano
    • 4-7 June, week after treatment in DLBCL
    • Brepoels L, Stroobants S, De Wolf-Peeters C, et al. Prospective evaluation on the value of FDG-PET/CT for response assessment in DLBCL after 1 week of R-CHOP (abstract 204). 10th International conference on malignant lymphoma ICML Lugano, 4-7 June 2008. This is the first clinical trial to demonstrate the value of FDG-PET one week after treatment in DLBCL.
    • (2008) This is the first clinical trial to demonstrate the value of FDG-PET , vol.one
    • Brepoels, L.1    Stroobants, S.2    De Wolf-Peeters, C.3
  • 11
    • 66249100124 scopus 로고    scopus 로고
    • Early interim FDG-PET during intensified BEACOPP therapy for advanced-stage Hodgkin disease shows a lower predictive value than during ABVD (abstract 0392)
    • This is the first study indicating that accuracy of early interim FDG-PET is therapy-dependent
    • Gallamini A, Viviani S, Bonfante V, et al. Early interim FDG-PET during intensified BEACOPP therapy for advanced-stage Hodgkin disease shows a lower predictive value than during ABVD (abstract 0392). Haematologica 2007; 92 (Suppl 2):143. This is the first study indicating that accuracy of early interim FDG-PET is therapy-dependent.
    • (2007) Haematologica , vol.92 , Issue.SUPPL. 2 , pp. 143
    • Gallamini, A.1    Viviani, S.2    Bonfante, V.3
  • 12
    • 25444437438 scopus 로고    scopus 로고
    • Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
    • Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16:1160-1168.
    • (2005) Ann Oncol , vol.16 , pp. 1160-1168
    • Hutchings, M.1    Mikhaeel, N.G.2    Fields, P.A.3
  • 13
    • 33947512956 scopus 로고    scopus 로고
    • Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
    • These are the consensus guidelines for response assessment by PET in lymphoma, which are considered mandatory for end-of-treatment evaluation in Hodgkin's lymphoma
    • Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571-578. These are the consensus guidelines for response assessment by PET in lymphoma, which are considered mandatory for end-of-treatment evaluation in Hodgkin's lymphoma.
    • (2007) J Clin Oncol , vol.25 , pp. 571-578
    • Juweid, M.E.1    Stroobants, S.2    Hoekstra, O.S.3
  • 14
    • 33947496614 scopus 로고    scopus 로고
    • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-586. These are the consensus guidelines for the integration of PET and CT results for response assessment in lymphoma, which are considered mandatory for end-of-treatment evaluation in Hodgkin's lymphoma.
    • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-586. These are the consensus guidelines for the integration of PET and CT results for response assessment in lymphoma, which are considered mandatory for end-of-treatment evaluation in Hodgkin's lymphoma.
  • 15
    • 30144432586 scopus 로고    scopus 로고
    • FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
    • Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107:52-59.
    • (2006) Blood , vol.107 , pp. 52-59
    • Hutchings, M.1    Loft, A.2    Hansen, M.3
  • 16
    • 35348834216 scopus 로고    scopus 로고
    • Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis
    • This is the most relevant prospective study in DLBCL, which shows that quantification of tumor FDG-uptake can markedly improve the accuracy of PET for prediction of patient outcome
    • Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007; 48:1626-1632. This is the most relevant prospective study in DLBCL, which shows that quantification of tumor FDG-uptake can markedly improve the accuracy of PET for prediction of patient outcome.
    • (2007) J Nucl Med , vol.48 , pp. 1626-1632
    • Lin, C.1    Itti, E.2    Haioun, C.3
  • 17
    • 0032757213 scopus 로고    scopus 로고
    • Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations
    • Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999; 35:1773-1782.
    • (1999) Eur J Cancer , vol.35 , pp. 1773-1782
    • Young, H.1    Baum, R.2    Cremerius, U.3
  • 18
    • 33846863991 scopus 로고    scopus 로고
    • Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce thecumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109:905-909. This is the first prospective study demonstrating that risk-adapted treatment strategies by means of early PET, may allow the reduction of chemotherapy, without impairment of outcome. These findings may have important consequences toward further patient management in advanced stage Hodgkin's lymphoma.
    • Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce thecumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109:905-909. This is the first prospective study demonstrating that risk-adapted treatment strategies by means of early PET, may allow the reduction of chemotherapy, without impairment of outcome. These findings may have important consequences toward further patient management in advanced stage Hodgkin's lymphoma.
  • 19
    • 66249095531 scopus 로고    scopus 로고
    • High incidence of false-positive PET scans in patients with aggressive non-Hodgkins lymphoma treated with rituximab-containing regimens (abstract 2401)
    • December
    • Han HS, Escalon MP, Serafini A, Lossos IS. High incidence of false-positive PET scans in patients with aggressive non-Hodgkins lymphoma treated with rituximab-containing regimens (abstract 2401). 48th Meeting American Society of Haematology, 7-12 December 2006.
    • (2006) 48th Meeting American Society of Haematology, 7-12
    • Han, H.S.1    Escalon, M.P.2    Serafini, A.3    Lossos, I.S.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.